Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,881 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Renal Diseases Clear all
Completed Phase 1 Interventional Results available

A Study of LY3113593 in Participants With Chronic Kidney Disease

NCT02604160
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
LY3113593, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge

NCT04351880
View directory record Official record
Conditions
Heart Failure, Copd, Liver Failure, Diabetes Mellitus, Cancer, End Stage Renal Disease
Interventions
Medically Tailored Meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Denver, Colorado • Lafayette, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 15, 2026, 1:32 PM EDT
Completed No phase listed Observational

Chitosan Chewing Gum Study in Dialysis Patients

NCT01770470
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Chitosan
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 15, 2026, 1:32 PM EDT
Completed No phase listed Observational

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

NCT01282762
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 15, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

NCT00090194
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

NCT02837237
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

NCT00143741
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Atorvastatin (Lipitor)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional

Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis

NCT04399941
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Venography, Intravascular ultrasound (IVUS), Image processing
Diagnostic Test · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Effects of Intradialytic Exercise as Assessed by Bioimpedance Analysis and Blood Volume Monitoring

NCT01273753
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Intradialytic exercise
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 15, 2026, 1:32 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Oct 15, 2026, 1:32 PM EDT
Terminated Not applicable Interventional Results available

Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients

NCT03539861
View directory record Official record
Conditions
End Stage Renal Disease, Acute Kidney Injury, Chronic Kidney Disease Stage 5
Interventions
Hemodialysis
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Not applicable Interventional

A Study AnalyZing a NovEl Wearable SeNsor for Remote PatIent Health Monitoring

NCT03993886
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Diseases
Interventions
CorBand, Activity Monitor, Bioimpedance spectrometer, ECG, respiratory rate sensor
Device · Other
Lead sponsor
ReThink Medical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Francisco, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 15, 2026, 1:32 PM EDT
Completed No phase listed Observational

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

NCT05640180
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
17,847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

NCT00761657
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
34
States / cities
Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 15, 2026, 1:32 PM EDT
Completed No phase listed Observational

Fluid Status of Dialysis Subjects

NCT07217041
View directory record Official record
Conditions
ESRD (End Stage Renal Disease)
Interventions
Not listed
Lead sponsor
HemoCept Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
EOS789, Placebo, Renvela
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System

NCT04198012
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
HemoCare™ Hemodialysis System
Device
Lead sponsor
Deka Research and Development
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Jackson, Mississippi • North Brunswick, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Network Interventions to Reduce Disparities in Living Kidney Donation

NCT05255757
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Script Intervention, Search Intervention
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Triferic AVNU Infusion Via Freedom Pump During Hemodialysis

NCT04689932
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic AVNU
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 15, 2026, 1:32 PM EDT
Completed No phase listed Observational

Transplant Patient Registry of Liver, Kidney and/or Pancreas

NCT00238693
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Liver Disease
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
13,767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

NCT03036839
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease

NCT03579693
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia, Frailty
Interventions
CoQ10, Nicotinamide riboside, Placebo
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Sit Less, Interact and Move More (SLIMM) 2 Study

NCT05173714
View directory record Official record
Conditions
Chronic Kidney Diseases, Obesity
Interventions
SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide
Behavioral · Drug
Lead sponsor
Srinvasan Beddhu
Other
Eligibility
20 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study

NCT00951977
View directory record Official record
Conditions
End Stage Renal Disease, Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
7,029 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 15, 2026, 1:32 PM EDT